Should You Buy Arrowhead Pharmaceuticals, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Arrowhead Pharmaceuticals, Inc. (ARWR) scores a robust 7.6/10 on our 32-signal Quality of Company framework. At the current market price of $70.67 and a $10.0B market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 0 of 6 CirclFi valuation models project upside for Arrowhead Pharmaceuticals, Inc. (ARWR) at $70.67 — the model consensus leans bearish, with a Quality Score of 7.6/10 and Value-Trap risk of 6/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Arrowhead Pharmaceuticals, Inc. (ARWR) in 2026?
What Is the Bull Case vs the Bear Case for Arrowhead Pharmaceuticals, Inc. (ARWR)?
| Bull case | Bear case — $3.16 target (-95.5%) |
|---|---|
| No active model projects meaningful upside for ARWR at $70.67. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $3.16 (-95.5%), suggesting that the market price embeds overly optimistic growth assumptions. |
| Industry headwind: manufacturing scale-up challenges represents a meaningful risk for Arrowhead Pharmaceuticals, Inc. and its Biotechnology peers. |
How Does ARWR Compare to Its Biotechnology Peers?
Valuation data pages: GYRE · JAZZ · NVAX · BDTX · KRYS · SPRO · CGON · SMMT · AGTX · EXEL · INCY
Which Other Stocks Score Like ARWR on Quality?
Closest companies to ARWR’s Quality of Company score of 7.6/10, across all industries.
- BIRK — Birkenstock Holding plc (QOC 7.6) · analysis
- PRU — Prudential Financial, Inc. (QOC 7.6) · analysis
- AERA — AI Era Corp. (QOC 7.6) · analysis
- PRG — PROG Holdings, Inc. (QOC 7.6) · analysis
- GBLI — Global Indemnity Group, LLC (QOC 7.6) · analysis
- MGEE — MGE Energy, Inc. (QOC 7.6) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does ARWR Appear In?
So Is Arrowhead Pharmaceuticals, Inc. (ARWR) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Arrowhead Pharmaceuticals, Inc. at $70.67. 6/6 models flag overvaluation, median fair value sits at $6.92 (-90.2%), and the risk-reward profile appears unfavorable. Quality at 7.6/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Arrowhead Pharmaceuticals, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About ARWR Stock?
Should I buy ARWR stock right now?
Based on CirclFi's multi-model analysis, 0 of 6 models see upside for ARWR at $70.67. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Arrowhead Pharmaceuticals, Inc.?
Key risks include: limited model coverage (6/13 active), reducing analytical confidence; wide model disagreement (449% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does ARWR compare to its competitors?
Among Biotechnology peers, ARWR holds a Quality Score of 7.6/10. Comparable companies include GYRE (QOC 7.6), JAZZ (QOC 7.6), NVAX (QOC 7.7). The relative ranking helps investors identify whether ARWR offers better fundamental quality than alternatives in the same sector.
Is ARWR a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ARWR's Quality Score of 7.6/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy ARWR at?
CirclFi does not provide target buy prices or price alerts. However, our 6 active models produce fair value estimates ranging from $3.16 to $17.39. At $70.67, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ARWR.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad